0
No votes yet
Safety

Safe Management of Chemotherapy: Infusion-Related Complications

Lisa Schulmeister
CJON 2014, 18(3), 283-287 DOI: 10.1188/14.CJON.283-287

The following is a reprint from Chapter 8 in Chemotherapy and Biotherapy Guidelines and Recommendations for Practice (Fourth Edition) by Martha Polovich, PhD, RN, AOCN®, MiKaela Olsen, MS, RN, AOCNS®, and Kristine B. LeFebvre, MSN, RN, AOCN® (Eds.). Copyright 2014 by the Oncology Nursing Society.

References 

Amphastar Pharmaceuticals. (2005). <i>Amphadase</i>® <i>(hyaluronidase injection)</i> [Package insert]. Rancho Cucamonga, CA: Author.

Arroyo, P.A., Perez, R.U., Feijoo, M.A.F., & Hernandez, M.A.C. (2010). Good clinical and cost outcomes using dexrazoxane to treat accidental epirubicin extravasation. <i>Journal of Cancer Research and Therapeutics, 6</i>, 573-574. doi:10.4103/0973-1482.77081

Biocodex Inc. (2011). <i>Totect</i>® <i>(dexrazoxane)</i> [Package insert]. San Bruno, CA: Author.

Bristol-Myers Squibb Co. (2011). <i>Taxol</i>® <i>(paclitaxel)</i> [Package insert]. Princeton, NJ: Author.

Celgene Corp. (2012). <i>Abraxane</i>® <i>for injectable suspension (paclitaxel protein-bound particles for injectable suspension) (albumin-bound)</i> [Package insert]. Summit, NJ: Author.

Dougherty, L., & Oakley, C. (2011). Advanced practice in the management of extravasation. <i>Cancer Nursing Practice, 10</i>(5), 16-22.

EMD Serono, Inc. (2008). <i>Novantrone</i>® <i>(mitoxantrone)</i> [Package insert]. Rockland, MA: Author.

Ener, R.A., Meglathery, S.B., & Styler, M. (2004). Extravasation of systemic hemato-oncological therapies. <i>Annals of Oncology, 15</i>, 858-862. doi:10.1093/annonc/mdh214

Goolsby, T.V., & Lombardo, F.A. (2006). Extravasation of chemotherapeutic agents: Prevention and treatment. <i>Seminars in Oncology, 33</i>, 139-143. doi:10.1053/j.seminoncol.2005.11.007

Goossens, G.A., Stas, M., Jérôme, M., & Moons, P. (2011). Systematic review: Malfunction of totally implantable venous access devices in cancer patients. <i>Supportive Care in Cancer, 19</i>, 883-898. doi:10.1007/s00520-011-1171-3

Halozyme Therapeutics Inc. (2012). <i>Hylenex</i>® <i>recombinant (hyaluronidase human injection)</i> [Package insert]. San Diego, CA: Author.

Langer, S.W. (2007). Dexrazoxane for anthracycline extravasation. <i>Expert Review of Anticancer Therapy, 7</i>, 1081-1088. doi:10.1586/14737140.7.8.1081

Langer, S.W. (2008). Treatment of anthracycline extravasation from centrally inserted venous catheters. <i>Oncology Reviews, 2</i>, 114-116. doi:10.1007/s12156-008-0065-1

Luedke, D.W., Kennedy, P.S., & Rietschel, R.L. (1979). Histopathogenesis of skin and subcutaneous injury induced by adriamycin. <i>Plastic and Reconstructive Surgery, 63</i>, 463-465. doi:10.1097/00006534197904000-00003

Lundbeck. (2012). <i>Mustargen</i>® <i>(mechlorethamine)</i> [Package insert]. Deerfield, IL: Author.

Mouridsen, H.T., Langer, S.W., Buter, J., Eidtmann, H., Rosti, G., de Wit, M., … Giaccone, G. (2006). Treatment of anthracycline extravasation with Savene (dexrazoxane): Results from two prospective clinical multicentre studies. <i>Annals of Oncology, 18</i>, 546-550.

sanofi-aventis U.S. LLC. (2007). <i>Taxotere</i>® <i>(docetaxel)</i> [Package insert]. Bridgewater, NJ: Author.

Sauerland, C., Engelking, C., Wickham, R., & Corbi, D. (2006). Vesicant extravasation part I: Mechanisms, pathogenesis, and nursing care to reduce risk. <i>Oncology Nursing Forum, 33</i>, 1134-1141. doi:10.1188/06.ONF.1134-1141

Schrijvers, D.L. (2003). Extravasation: A dreaded complication of chemotherapy. <i>Annals of Oncology, 14</i>(Suppl. 3), iii26-iii30. doi:10.1093/annonc/mdg744

Schulmeister, L. (2011). Extravasation management: Clinical update. <i>Seminars in Oncology Nursing, 27</i>, 82-90. doi:10.1016/j.soncn.2010.11.010

Stanford, B.L., & Hardwicke, F. (2003). A review of clinical experience with paclitaxel extravasations. <i>Supportive Care in Cancer, 11</i>, 270-277. doi:10.1007/s00520-003-0441-0

Uges, J.W.F., Vollaard, A.M., Wilms, E.B., & Brouwer, R.E. (2006). Intrapleural extravasation of epirubicin, 5-fluouracil, and cyclophosphamide, treated with dexrazoxane. <i>International Journal of Clinical Oncology, 11</i>, 467-470. doi:10.1007/s10147-006-0598-x

Wickham, R., Engelking, C., Sauerland, C., & Corbi, D. (2006). Vesicant extravasation part II: Evidence-based management and continuing controversies. <i>Oncology Nursing Forum, 33</i>, 1143-1150. doi:10.1188/06/ONF.1143-1150